Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible
Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line trea...
Gespeichert in:
| Veröffentlicht in: | Journal of Cancer 2018-01, Vol.9 (6), p.1121-1126 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1126 |
|---|---|
| container_issue | 6 |
| container_start_page | 1121 |
| container_title | Journal of Cancer |
| container_volume | 9 |
| creator | Sapalidis, Konstantinos Zarogoulidis, Paul Huang, Haidong Bai, Chong Wen, Yuting Wang, Li Boniou, Konstantina Karapantzos, Ilias Karapantzou, Chrysanthi Karanikas, Michael Thomaidis, Vasilis Kosmidis, Christoforos Sardeli, Chrysanthi Benhassen, Naim Man, Yan-Gao Florou, Maria C Mantalovas, Stylianos Laskou, Stella Giannakidis, Dimitris Koulouris, Charilaos Amaniti, Aikaterini Kesisoglou, Isaak Hohenforst-Schmidt, Wolfgang |
| description | Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab. |
| doi_str_mv | 10.7150/jca.24397 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5868180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2019043731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ca76e6f4c26c921aa2b6aabe41ec74460e35737e0e85b3d1b50465938aa4f68d3</originalsourceid><addsrcrecordid>eNpVkdtKxDAQhoMorqx74QtIL_Wia9KkSYugLMXDwoKCeh2m6dSNtOmatMK-vfWIzs0MzMc_h5-QI0bniqX07MXAPBE8VzvkgGVcxbmUYvdPPSGzEF7oGDxPlOD7ZJLkacZUnhyQh6VbQ4NVtGzbwXX9Gj1sttGiaq2zoffQ285Fdeej1eCeowKcQX8eXdW1NRZdfxkV6HuwrtlG910ItmzwkOzV0AScfecpebq-eixu49XdzbJYrGLDVdrHBpREWQuTSJMnDCApJUCJgqFRQkiKPFVcIcUsLXnFypQKmeY8AxC1zCo-JRdfupuhbLEy4zoeGr3xtgW_1R1Y_b_j7Fo_d286zWTGMjoKnHwL-O51wNDr1gaDTQMOuyHohLKcCq44G9HTL9T48UqP9e8YRvWHD3r0QX_6MLLHf_f6JX--zt8BBm2Esw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019043731</pqid></control><display><type>article</type><title>Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Sapalidis, Konstantinos ; Zarogoulidis, Paul ; Huang, Haidong ; Bai, Chong ; Wen, Yuting ; Wang, Li ; Boniou, Konstantina ; Karapantzos, Ilias ; Karapantzou, Chrysanthi ; Karanikas, Michael ; Thomaidis, Vasilis ; Kosmidis, Christoforos ; Sardeli, Chrysanthi ; Benhassen, Naim ; Man, Yan-Gao ; Florou, Maria C ; Mantalovas, Stylianos ; Laskou, Stella ; Giannakidis, Dimitris ; Koulouris, Charilaos ; Amaniti, Aikaterini ; Kesisoglou, Isaak ; Hohenforst-Schmidt, Wolfgang</creator><creatorcontrib>Sapalidis, Konstantinos ; Zarogoulidis, Paul ; Huang, Haidong ; Bai, Chong ; Wen, Yuting ; Wang, Li ; Boniou, Konstantina ; Karapantzos, Ilias ; Karapantzou, Chrysanthi ; Karanikas, Michael ; Thomaidis, Vasilis ; Kosmidis, Christoforos ; Sardeli, Chrysanthi ; Benhassen, Naim ; Man, Yan-Gao ; Florou, Maria C ; Mantalovas, Stylianos ; Laskou, Stella ; Giannakidis, Dimitris ; Koulouris, Charilaos ; Amaniti, Aikaterini ; Kesisoglou, Isaak ; Hohenforst-Schmidt, Wolfgang</creatorcontrib><description>Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.24397</identifier><identifier>PMID: 29581792</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Journal of Cancer, 2018-01, Vol.9 (6), p.1121-1126</ispartof><rights>Ivyspring International Publisher 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ca76e6f4c26c921aa2b6aabe41ec74460e35737e0e85b3d1b50465938aa4f68d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868180/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868180/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29581792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sapalidis, Konstantinos</creatorcontrib><creatorcontrib>Zarogoulidis, Paul</creatorcontrib><creatorcontrib>Huang, Haidong</creatorcontrib><creatorcontrib>Bai, Chong</creatorcontrib><creatorcontrib>Wen, Yuting</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Boniou, Konstantina</creatorcontrib><creatorcontrib>Karapantzos, Ilias</creatorcontrib><creatorcontrib>Karapantzou, Chrysanthi</creatorcontrib><creatorcontrib>Karanikas, Michael</creatorcontrib><creatorcontrib>Thomaidis, Vasilis</creatorcontrib><creatorcontrib>Kosmidis, Christoforos</creatorcontrib><creatorcontrib>Sardeli, Chrysanthi</creatorcontrib><creatorcontrib>Benhassen, Naim</creatorcontrib><creatorcontrib>Man, Yan-Gao</creatorcontrib><creatorcontrib>Florou, Maria C</creatorcontrib><creatorcontrib>Mantalovas, Stylianos</creatorcontrib><creatorcontrib>Laskou, Stella</creatorcontrib><creatorcontrib>Giannakidis, Dimitris</creatorcontrib><creatorcontrib>Koulouris, Charilaos</creatorcontrib><creatorcontrib>Amaniti, Aikaterini</creatorcontrib><creatorcontrib>Kesisoglou, Isaak</creatorcontrib><creatorcontrib>Hohenforst-Schmidt, Wolfgang</creatorcontrib><title>Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.</description><subject>Research Paper</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkdtKxDAQhoMorqx74QtIL_Wia9KkSYugLMXDwoKCeh2m6dSNtOmatMK-vfWIzs0MzMc_h5-QI0bniqX07MXAPBE8VzvkgGVcxbmUYvdPPSGzEF7oGDxPlOD7ZJLkacZUnhyQh6VbQ4NVtGzbwXX9Gj1sttGiaq2zoffQ285Fdeej1eCeowKcQX8eXdW1NRZdfxkV6HuwrtlG910ItmzwkOzV0AScfecpebq-eixu49XdzbJYrGLDVdrHBpREWQuTSJMnDCApJUCJgqFRQkiKPFVcIcUsLXnFypQKmeY8AxC1zCo-JRdfupuhbLEy4zoeGr3xtgW_1R1Y_b_j7Fo_d286zWTGMjoKnHwL-O51wNDr1gaDTQMOuyHohLKcCq44G9HTL9T48UqP9e8YRvWHD3r0QX_6MLLHf_f6JX--zt8BBm2Esw</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Sapalidis, Konstantinos</creator><creator>Zarogoulidis, Paul</creator><creator>Huang, Haidong</creator><creator>Bai, Chong</creator><creator>Wen, Yuting</creator><creator>Wang, Li</creator><creator>Boniou, Konstantina</creator><creator>Karapantzos, Ilias</creator><creator>Karapantzou, Chrysanthi</creator><creator>Karanikas, Michael</creator><creator>Thomaidis, Vasilis</creator><creator>Kosmidis, Christoforos</creator><creator>Sardeli, Chrysanthi</creator><creator>Benhassen, Naim</creator><creator>Man, Yan-Gao</creator><creator>Florou, Maria C</creator><creator>Mantalovas, Stylianos</creator><creator>Laskou, Stella</creator><creator>Giannakidis, Dimitris</creator><creator>Koulouris, Charilaos</creator><creator>Amaniti, Aikaterini</creator><creator>Kesisoglou, Isaak</creator><creator>Hohenforst-Schmidt, Wolfgang</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180101</creationdate><title>Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible</title><author>Sapalidis, Konstantinos ; Zarogoulidis, Paul ; Huang, Haidong ; Bai, Chong ; Wen, Yuting ; Wang, Li ; Boniou, Konstantina ; Karapantzos, Ilias ; Karapantzou, Chrysanthi ; Karanikas, Michael ; Thomaidis, Vasilis ; Kosmidis, Christoforos ; Sardeli, Chrysanthi ; Benhassen, Naim ; Man, Yan-Gao ; Florou, Maria C ; Mantalovas, Stylianos ; Laskou, Stella ; Giannakidis, Dimitris ; Koulouris, Charilaos ; Amaniti, Aikaterini ; Kesisoglou, Isaak ; Hohenforst-Schmidt, Wolfgang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ca76e6f4c26c921aa2b6aabe41ec74460e35737e0e85b3d1b50465938aa4f68d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sapalidis, Konstantinos</creatorcontrib><creatorcontrib>Zarogoulidis, Paul</creatorcontrib><creatorcontrib>Huang, Haidong</creatorcontrib><creatorcontrib>Bai, Chong</creatorcontrib><creatorcontrib>Wen, Yuting</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Boniou, Konstantina</creatorcontrib><creatorcontrib>Karapantzos, Ilias</creatorcontrib><creatorcontrib>Karapantzou, Chrysanthi</creatorcontrib><creatorcontrib>Karanikas, Michael</creatorcontrib><creatorcontrib>Thomaidis, Vasilis</creatorcontrib><creatorcontrib>Kosmidis, Christoforos</creatorcontrib><creatorcontrib>Sardeli, Chrysanthi</creatorcontrib><creatorcontrib>Benhassen, Naim</creatorcontrib><creatorcontrib>Man, Yan-Gao</creatorcontrib><creatorcontrib>Florou, Maria C</creatorcontrib><creatorcontrib>Mantalovas, Stylianos</creatorcontrib><creatorcontrib>Laskou, Stella</creatorcontrib><creatorcontrib>Giannakidis, Dimitris</creatorcontrib><creatorcontrib>Koulouris, Charilaos</creatorcontrib><creatorcontrib>Amaniti, Aikaterini</creatorcontrib><creatorcontrib>Kesisoglou, Isaak</creatorcontrib><creatorcontrib>Hohenforst-Schmidt, Wolfgang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sapalidis, Konstantinos</au><au>Zarogoulidis, Paul</au><au>Huang, Haidong</au><au>Bai, Chong</au><au>Wen, Yuting</au><au>Wang, Li</au><au>Boniou, Konstantina</au><au>Karapantzos, Ilias</au><au>Karapantzou, Chrysanthi</au><au>Karanikas, Michael</au><au>Thomaidis, Vasilis</au><au>Kosmidis, Christoforos</au><au>Sardeli, Chrysanthi</au><au>Benhassen, Naim</au><au>Man, Yan-Gao</au><au>Florou, Maria C</au><au>Mantalovas, Stylianos</au><au>Laskou, Stella</au><au>Giannakidis, Dimitris</au><au>Koulouris, Charilaos</au><au>Amaniti, Aikaterini</au><au>Kesisoglou, Isaak</au><au>Hohenforst-Schmidt, Wolfgang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>9</volume><issue>6</issue><spage>1121</spage><epage>1126</epage><pages>1121-1126</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>29581792</pmid><doi>10.7150/jca.24397</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1837-9664 |
| ispartof | Journal of Cancer, 2018-01, Vol.9 (6), p.1121-1126 |
| issn | 1837-9664 1837-9664 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5868180 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Research Paper |
| title | Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A45%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhaled%20Immunotherapy%20Administration%20for%20Lung%20Cancer;%20Efficient?%20Certainly%20Possible&rft.jtitle=Journal%20of%20Cancer&rft.au=Sapalidis,%20Konstantinos&rft.date=2018-01-01&rft.volume=9&rft.issue=6&rft.spage=1121&rft.epage=1126&rft.pages=1121-1126&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.24397&rft_dat=%3Cproquest_pubme%3E2019043731%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019043731&rft_id=info:pmid/29581792&rfr_iscdi=true |